Literature DB >> 32111377

Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity.

Ryan S Funk1, Nasreen J Talib2, Kanecia O Zimmerman3, Leon van Haandel4, Mara L Becker5.   

Abstract

Methotrexate is used to treat autoimmune and oncologic diseases in children with Down syndrome. However, increased methotrexate-related toxicity is reported in this population. We evaluated differences in the concentrations and distribution of erythrocyte folates in children with Down syndrome as a potential basis for this enhanced toxicity.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Down syndrome; folates; pediatrics; precision medicine; toxicity

Mesh：

Substances：

Year:  2020        PMID： 32111377      PMCID： PMC7247922          DOI： 10.1016/j.jpeds.2020.01.032

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  27 in total

1.  Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006.

Authors:  Samantha E Parker; Cara T Mai; Mark A Canfield; Russel Rickard; Ying Wang; Robert E Meyer; Patrick Anderson; Craig A Mason; Julianne S Collins; Russell S Kirby; Adolfo Correa
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-09-28

Review 2.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

3.  Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability.

Authors:  Mara L Becker; Leon van Haandel; Roger Gaedigk; Bradley Thomas; Mark F Hoeltzel; Andrew Lasky; Hongying Dai; John Stobaugh; James S Leeder
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

4.  Clinical Features and Treatment of Down Syndrome Arthropathy: Experience from Two US Tertiary Hospitals.

Authors:  Jordan T Jones; Nasreen Talib; Daniel Lovell; Mara L Becker
Journal:  Paediatr Drugs       Date:  2019-02       Impact factor: 3.022

5.  Regulation of folate and one-carbon metabolism in mammalian cells. IV. Role of folylpoly-gamma-glutamate synthetase in methotrexate metabolism and cytotoxicity.

Authors:  J S Kim; K E Lowe; B Shane
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

6.  The arthropathy of Down syndrome: an underdiagnosed and under-recognized condition.

Authors:  Harbir Juj; Helen Emery
Journal:  J Pediatr       Date:  2008-09-10       Impact factor: 4.406

7.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

Authors:  B N Cronstein; D Naime; E Ostad
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization.

Authors:  T L Yang-Feng; Y Y Ma; R Liang; P D Prasad; F H Leibach; V Ganapathy
Journal:  Biochem Biophys Res Commun       Date:  1995-05-25       Impact factor: 3.575

9.  Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity.

Authors:  M Peeters; A Poon
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

10.  Mutations in the Chinese hamster ovary cell GART gene of de novo purine synthesis.

Authors:  Aaron J Knox; Christine Graham; John Bleskan; Gary Brodsky; David Patterson
Journal:  Gene       Date:  2008-10-21       Impact factor: 3.688
View more
  1 in total

Review 1.  Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care.

Authors:  Shilpa A Shahani; Erin L Marcotte
Journal:  Front Pediatr       Date:  2022-09-26       Impact factor: 3.569
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.